Active Ingredient History
Pirfenidone is a synthetic antifibrotic agent indicated for the treatment of idiopathic pulmonary fibrosis as Esbriet. Pirfenidone inhibits fibroblast, epidermal, platelet-derived, and transforming beta-1 growth factors. It also inhibits DNA synthesis and the production of mRNA for collagen types I and III, resulting in a reduction in radiation-induced fibrosis. Pirfenidone has demonstrated activity in multiple fibrotic conditions however the exact mechanism of action of pirfenidone in the treatment of IPF has not been established. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acne Vulgaris (Phase 1/Phase 2)
Acute Kidney Injury (Phase 4)
Acute Lung Injury (Phase 2)
Acute-On-Chronic Liver Failure (Phase 2)
Albinism (Phase 2)
Albinism, Oculocutaneous (Phase 2)
Albuminuria (Phase 3)
Allografts (Phase 2)
Alveolitis, Extrinsic Allergic (Phase 2/Phase 3)
Arthritis, Rheumatoid (Phase 2)
Bronchiolitis (Phase 2/Phase 3)
Bronchiolitis Obliterans (Phase 1)
Burns (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Cardiomyopathy, Hypertrophic (Phase 2)
Connective Tissue Diseases (Phase 4)
COVID-19 (Phase 4)
Dermatomyositis (Phase 4)
Diabetes Mellitus (Phase 1/Phase 2)
Diabetic Foot (Phase 3)
Diabetic Nephropathies (Phase 3)
Drug Interactions (Phase 1)
Drugs, Investigational (Phase 4)
Endomyocardial Fibrosis (Phase 2)
Fibrosis (Phase 2)
Genetic Diseases, Inborn (Phase 2)
Glomerulosclerosis, Focal Segmental (Phase 2)
Graft vs Host Disease (Phase 1)
Healthy Volunteers (Phase 1)
Heart Failure (Phase 2)
Hepatitis C, Chronic (Phase 2)
Hermanski-Pudlak Syndrome (Phase 2)
Keloid (Phase 3)
Leiomyoma (Phase 2)
Liver Cirrhosis (Phase 2)
Lung Diseases (Phase 3)
Lung Diseases, Interstitial (Phase 4)
Lung Neoplasms (Phase 2)
Lung Transplantation (Phase 2/Phase 3)
Metabolism, Inborn Errors (Phase 2)
Neoplasms (Phase 1)
Nephrotic Syndrome (Phase 2)
Neurofibroma, Plexiform (Phase 2)
Neurofibromatoses (Phase 2)
Neurofibromatosis 1 (Phase 2)
Pancreatitis (Phase 1/Phase 2)
Platelet Storage Pool Deficiency (Phase 2)
Pneumococcal Infections (Phase 2)
Pneumoconiosis (Phase 3)
Pneumonia (Phase 3)
Precancerous Conditions (Phase 1)
Proteinuria (Phase 2)
Pulmonary Fibrosis (Phase 2/Phase 3)
Radiation Pneumonitis (Phase 2)
Radiotherapy (Phase 2)
Renal Insufficiency (Phase 2)
Renal Insufficiency, Chronic (Phase 2)
Respiratory Distress Syndrome (Phase 3)
Sarcoidosis, Pulmonary (Phase 4)
Scleroderma, Systemic (Phase 2/Phase 3)
Sclerosis (Phase 3)
Sepsis (Phase 4)
Silicosis (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
